UNSPSC 51144124: Lisdexamfetamine

This classification denotes an anorexiant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) H645GUL8KJ. European Medicines Agency schedules Lisdexamfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32170. Lisdexamfetamine generally arises in the molecular formula C15H25N3O.

The term LISDEXAMFETAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 20, no. 3, 2006, list 56.) Most nations, for tariff and trade purposes, schedule lisdexamfetamine under HS 29242990 and SITC 51479. As of Q4 2014, LISDEXAMFETAMINE remains US FDA's Preferred Term for this commodity. Lisdexamfetamine bears US NLM identifiers UMLS ID C1873633 and NCI Concept Code C75114. SMILES: CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N.

UNSPSC 51144124 Lisdexamfetamine is a Commodity code that in practice encompasses pharmaceutical procurement by state and local health agencies, not the single active pharmaceutical ingredient its name suggests. Recent state and local solicitations under this code show government health departments, county public health systems, and multistate cooperative purchasing alliances buying controlled and over-the-counter pharmaceutical products through competitive bidding, with issuing bodies including county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate purchasing cooperatives (Minnesota Department of Administration). The scope of work reflects direct pharmaceutical procurement for community health distribution, pharmacy benefit program management, and generic multi-source pharmaceutical supply agreements through authorized wholesalers, with vendors required to maintain cGMP certification, Drug Supply Chain Security Act compliance, and specific insurance coverages including commercial general liability and professional liability.

Activity under the code concentrates in Florida and the upper Midwest, with recent opportunities spanning Texas. A January 2026 RFP from the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration's Office of State Procurement sought multiple contracts for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers and maintain two-year contract terms with optional extensions. Seminole County, Florida issued an IFB (No. IFB60459723LAS) in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due July 26, 2023. The Texas Health and Human Services Commission posted an RFI in April 2026 (No. HHS0017013) to gather market intelligence on direct-to-manufacturer prescription programs, reflecting early-stage procurement strategy development rather than an active competitive opportunity.